Zeluvalimab is under clinical development by Amgen and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zeluvalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zeluvalimab overview
AMG-404 is under development for the treatment of advanced solid tumors and relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL), malignant mesothelioma, pancreatic cancer, squamous non-small cell lung cancer, small cell lung cancer, ovarian cancer, melanoma, head and neck squamous cell cancer, urothelial cancer, gastric or GEJ adenocarcinoma, esophageal (squamous, PD-L1 positive), cervical cancer, hepatocellular carcinoma, merkel cell carcinoma, squamous cell carcinoma of the skin, renal cell carcinoma, thymic carcinoma and nasopharyngeal carcinoma. The drug candidate is administered through intravenous route. It acts by targeting programmed cell death 1.
It was also under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Amgen overview
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines for the treatment of cardiovascular conditions, oncology/hematology, inflammation, bone health, neurological disorders and nephrology conditions. The company analyzes the difficulties of disease and understands the fundamentals of human biology to develop products harnessing advanced human genetics. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has a presence in Asia Pacific, Europe, the Middle East, the Americas and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
For a complete picture of Zeluvalimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
